Edition:
United Kingdom

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

42.59USD
18 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$42.59
Open
$43.52
Day's High
$43.70
Day's Low
$42.50
Volume
99,909
Avg. Vol
48,305
52-wk High
$56.00
52-wk Low
$32.25

Latest Key Developments (Source: Significant Developments)

Wave Life Sciences DMD Trial Selected For FDA Complex Innovative Trial Designs Pilot Program
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES DUCHENNE MUSCULAR DYSTROPHY CLINICAL TRIAL SELECTED FOR FDA COMPLEX INNOVATIVE TRIAL DESIGNS PILOT PROGRAM.WAVE LIFE SCIENCES LTD - SUVODIRSEN (WVE-210201) PHASE 2/3 TRIAL CHOSEN BY FDA IN INAUGURAL ROUND OF PILOT PROGRAM.WAVE LIFE SCIENCES-ANTICIPATES INITIATING PHASE 2/3 EFFICACY, SAFETY CLINICAL TRIAL OF SUVODIRSEN IN DMD PATIENTS AMENABLE TO EXON 51 SKIPPING IN 2019.  Full Article

Wave Life's WVE-210201 Receives Positive Opinion For Orphan Drug Designation In EU
Monday, 2 Jul 2018 

July 2 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR WVE-210201.WAVE LIFE SCIENCES LTD - SAFETY DATA FROM PHASE 1 CLINICAL TRIAL OF WVE-210201 IS EXPECTED IN Q3 OF 2018.  Full Article

Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA.WAVE LIFE SCIENCES - WVE-3972-01 DEMONSTRATED SUBSTANTIAL REDUCTION IN DISEASE-ASSOCIATED BIOMARKERS & SUPERIOR POTENCY TO STEREORANDOM OLIGONUCLEOTIDES.WAVE LIFE SCIENCES LTD - CO INTENDS TO INITIATE CLINICAL TRIALS OF WVE-3972-01 IN ALS AND FTD IN Q4 2018.  Full Article

Wave Life Sciences Q3 net loss of $26.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Wave Life Sciences Ltd ::Wave Life Sciences reports third quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - ‍ Wave reported a net loss of $26.1 million for Q3 of 2017, as compared to a net loss of $17.5 million for Q3 of 2016​.Wave Life Sciences Ltd - qtrly loss per share $0.94‍​.Wave Life Sciences -‍ expects capital resources available, anticipated milestone payments to be sufficient to fund expenses, capex needs into mid-2019​.  Full Article

Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD).Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​.  Full Article